Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
Retrieved on:
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Finance, Oncology, Health, FDA, Professional Services, Clinical Trials, Congress, Bristol Myers Squibb, NYSE, PASI, Coronary thrombosis, Journal of the European Academy of Dermatology and Venereology, Abstract, Research, Circulatory system, Aes, AE, Risk, Bolivian National Congress, 1985–1989, Malignancy, Death, University, Week, MPH, Safety, Psoriasis, Conditional sentence, Psoriasis Area and Severity Index, Shingles, Plaque, CPU socket, Head, PSO, LTE, BMY, Patient, Pharmaceutical industry, Dermatology, MD, Venereology, Immunology, Deucravacitinib, TYK2
Bristol Myers Squibb (NYSE:BMY) today announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.
Key Points:
- Bristol Myers Squibb (NYSE:BMY) today announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.
- Sotyktu demonstrated a consistent safety profile with no increases in the rates of adverse events (AEs) or serious AEs over time, and no emergence of any new safety signals.
- The efficacy analysis assessed 513 patients who received continuous Sotyktu treatment from Day 1 in the pivotal POETYK PSO-1 and POETYK PSO-2 trials and transitioned to the LTE trial.
- “These new data validate the potential of Sotyktu to provide long-term, clinically relevant improvement for individuals living with moderate-to-severe plaque psoriasis.”
Bristol Myers Squibb thanks the patients and investigators involved in the POETYK PSO clinical trial program.